<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Palvella Therapeutics, Inc — News on 6ix</title>
<link>https://6ix.com/company/palvella-therapeutics-inc</link>
<description>Latest news and press releases for Palvella Therapeutics, Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/palvella-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b2b178dffbe2df112484.webp</url>
<title>Palvella Therapeutics, Inc</title>
<link>https://6ix.com/company/palvella-therapeutics-inc</link>
</image>
<item>
<title>Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-host-first-quarter-2026-financial-results-and-corporate-update-conference-call-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-host-first-quarter-2026-financial-results-and-corporate-update-conference-call-on-may-7-2026</guid>
<pubDate>Thu, 30 Apr 2026 11:30:00 GMT</pubDate>
<description>WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will report its first quarter 2026 financial results before market open on Thursday,</description>
</item>
<item>
<title>Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-present-qtorintm-rapamycin-results-from-phase-3-selva-and-phase-2-toiva-studies-at-the-international-society-for-the-study-of-vascular-anomalies-world-congress-2026</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-present-qtorintm-rapamycin-results-from-phase-3-selva-and-phase-2-toiva-studies-at-the-international-society-for-the-study-of-vascular-anomalies-world-congress-2026</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET WAYNE, Pa., April 20, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which t</description>
</item>
<item>
<title>Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-appoints-john-d-doux-md-mba-dermatologist-and-recognized-leader-in-rare-skin-diseases-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-appoints-john-d-doux-md-mba-dermatologist-and-recognized-leader-in-rare-skin-diseases-to-board-of-directors</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership</description>
</item>
<item>
<title>Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-appoints-accomplished-commercial-leader-kent-taylor-as-senior-vice-president-of-sales</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-appoints-accomplished-commercial-leader-kent-taylor-as-senior-vice-president-of-sales</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis</description>
</item>
<item>
<title>Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in</description>
</item>
<item>
<title>Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-scientific-publication-in-journal-of-vascular-anomalies-highlighting-the-infiltrative-growth-and-therapeutic-challenges-of-microcystic-lymphatic-malformations</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-scientific-publication-in-journal-of-vascular-anomalies-highlighting-the-infiltrative-growth-and-therapeutic-challenges-of-microcystic-lymphatic-malformations</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial</description>
</item>
<item>
<title>Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-highlights-continued-progress-across-rare-skin-disease-pipeline-with-two-poster-presentations-at-the-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-highlights-continued-progress-across-rare-skin-disease-pipeline-with-two-poster-presentations-at-the-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven</description>
</item>
<item>
<title>Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-host-full-year-2025-financial-results-conference-call-and-provide-a-corporate-update-on-march-31-2026</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-host-full-year-2025-financial-results-conference-call-and-provide-a-corporate-update-on-march-31-2026</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-rare-disease-commercial-leader-jennifer-j-mcdonough-as-senior-vice-president-of-market-access-and-patient-services</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-strengthens-leadership-team-with-appointment-of-rare-disease-commercial-leader-jennifer-j-mcdonough-as-senior-vice-president-of-market-access-and-patient-services</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead</description>
</item>
<item>
<title>Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-issuance-of-european-patent-covering-anhydrous-compositions-of-rapamycin</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-issuance-of-european-patent-covering-anhydrous-compositions-of-rapamycin</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development</description>
</item>
<item>
<title>Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-launches-beyond-mlm-disease-awareness-campaign-for-microcystic-lymphatic-malformations-in-collaboration-with-leading-lymphatic-vascular-and-dermatology-nonprofit-organizations-2</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-launches-beyond-mlm-disease-awareness-campaign-for-microcystic-lymphatic-malformations-in-collaboration-with-leading-lymphatic-vascular-and-dermatology-nonprofit-organizations-2</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers, and healthcare professionals Campaign developed and launched in close</description>
</item>
<item>
<title>Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-exercise-in-full-of-the-underwriters-option-to-purchase-additional-shares</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-closing-of-upsized-public-offering-of-common-stock-and-exercise-in-full-of-the-underwriters-option-to-purchase-additional-shares</guid>
<pubDate>Mon, 02 Mar 2026 12:30:00 GMT</pubDate>
<description>WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it closed its previously announced upsized public offering on February 27, 2026. The offering consisted</description>
</item>
<item>
<title>Palvella Therapeutics Announces Pricing of Upsized Public Offering</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-pricing-of-upsized-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-pricing-of-upsized-public-offering</guid>
<pubDate>Thu, 26 Feb 2026 00:57:00 GMT</pubDate>
<description>WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the pricing of its upsized public offering of 1,600,000 shares of its common stock at a price to the public o</description>
</item>
<item>
<title>Palvella Therapeutics Announces Proposed Public Offering</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-proposed-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-proposed-public-offering</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. In add</description>
</item>
<item>
<title>Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-positive-topline-results-from-phase-3-selva-clinical-study-of-qtorintm-39percent-rapamycin-anhydrous-gel-qtorintm-rapamycin-in-microcystic-lymphatic-malformations</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-positive-topline-results-from-phase-3-selva-clinical-study-of-qtorintm-39percent-rapamycin-anhydrous-gel-qtorintm-rapamycin-in-microcystic-lymphatic-malformations</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>Primary endpoint met with statistically significant improvement (mean change of +2.13;</description>
</item>
<item>
<title>Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorintm-39percent-rapamycin-anhydrous-gel-qtorintm-rapamycin-in-microcystic-lymphatic-malformations-1</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorintm-39percent-rapamycin-anhydrous-gel-qtorintm-rapamycin-in-microcystic-lymphatic-malformations-1</guid>
<pubDate>Mon, 23 Feb 2026 22:00:00 GMT</pubDate>
<description>Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ETWAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that i</description>
</item>
<item>
<title>Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations </title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorintm-39percent-rapamycin-anhydrous-gel-qtorintm-rapamycin-in-microcystic-lymphatic-malformations</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-to-host-conference-call-to-discuss-topline-results-from-phase-3-selva-clinical-trial-of-qtorintm-39percent-rapamycin-anhydrous-gel-qtorintm-rapamycin-in-microcystic-lymphatic-malformations</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella</description>
</item>
<item>
<title>Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-scientific-publication-123000582</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-announces-scientific-publication-123000582</guid>
<pubDate>Mon, 02 Feb 2026 12:30:00 GMT</pubDate>
<description>Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of a standardized, FDA-approved statin therapy evaluated in rigorous, well-designed clinical trials WAYNE, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-provides-corporate-2026-123000294</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-provides-corporate-2026-123000294</guid>
<pubDate>Fri, 09 Jan 2026 12:30:00 GMT</pubDate>
<description>Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending positive results, an NDA submission is planned for the second half of 2026 Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic LMs which has the potential to become the first FDA-approved therapy and a first-line, standard-of-care treatment for this serious,</description>
</item>
<item>
<title>Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs</title>
<link>https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-strengthens-leadership-team-123000407</link>
<guid isPermaLink="true">https://6ix.com/company/palvella-therapeutics-inc/news/palvella-therapeutics-strengthens-leadership-team-123000407</guid>
<pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
<description>Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA®, povorcitinib, ILUMYA®, ODOMZO®, REMICADE®, and STELARA® Dr. Patel to lead Palvella’s Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company’s QTORIN™ programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous</description>
</item>
</channel>
</rss>